Status:
RECRUITING
Immun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer
Lead Sponsor:
Istanbul Training and Research Hospital
Conditions:
Breast Cancer Metastatic
Breast Carcinoma
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Invasive ductal carcinoma is the most common type of invasive breast cancer. In cases where axillary lymph node metastases are diagnosed through screening, they can be found in up to 25% of cases, and...
Detailed Description
The most common cancer in women worldwide and the leading cause of death among those aged 20-59 is breast cancer. Invasive breast cancers are primarily classified as ductal and lobular. However, speci...
Eligibility Criteria
Inclusion
- Histopathologically proven invasive ductal carcinoma
- Patients who will have neoadjuvant therapy
Exclusion
- The fine-needle aspiration biopsy (FNAB) result of the suspected metastatic lymph node is negative.
- The FNAB result of the presumed healthy lymph node is malignant.
- They refuse to participate in the study.
- They have another primary malignancy.
- They are pregnant.
- They have a history of immunodeficiency.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07003009
Start Date
January 1 2024
End Date
October 1 2025
Last Update
June 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istanbul Training and Research Hospital
Istanbul, Turkey (Türkiye), 34098